Torrent Pharmaceuticals Limited (TORNTPHARM) — Financial Results | 20 May 2025(2 announcements)
Torrent Pharmaceuticals reported FY25 revenue of ₹9,682 crores, up 7% YoY, with net profit of ₹1,888 crores and a proposed final dividend of ₹6 per share. The company reversed ₹151 crores in deferred tax due to new tax regime transition, while maintaining a strong 19.5% net profit margin. It proposed a ₹5,000 crore capital raise via QIP and appointed Aman Mehta as Managing Director effective August 1, 2025, pending shareholder approval.
Torrent Pharmaceuticals reported consolidated revenue of ₹11,516 crores for FY25, up 7% YoY, with net profit of ₹1,818 crores (15% YoY growth after adjusting for exceptional items). The company declared an interim dividend of Rs 26 per share and proposed a final dividend of Rs 6 per share. Key growth drivers included 12% revenue growth in India and margin expansion to 33.1% Op EBITDA margin. Aman Mehta was appointed Managing Director effective August 1, 2025, pending shareholder approval.
About Torrent Pharmaceuticals Limited (TORNTPHARM)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when TORNTPHARM files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track TORNTPHARM — Free💡 Ask AI about this filing
📊 More TORNTPHARM filings
- Announcement — 11 August 2026 Torrent Pharmaceuticals announced its participation in an investors' meet hosted by Emkay on August ...
- Announcement — 11 August 2026 Torrent Pharmaceuticals announced that NSE Sustainability Ratings and Analytics assigned the company...
- 🔴 Financial Results — 4 August 2026 Torrent Pharmaceuticals announced a conference call transcript for Q1 FY26 results on August 4, 2026...
- 🟡 Board Meeting — 1 August 2026 Torrent Pharmaceuticals announced the cessation of Ameera Shah as an Independent Director effective ...
- 🔴 Financial Results — 30 July 2026 Torrent Pharmaceuticals announced that the audio recording of its conference call discussing financi...
🔥 Also filed on 20 May 2025
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when TORNTPHARM files new disclosures
Track TORNTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track TORNTPHARM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research